On December 10 1998 in Stockholm, three American scientists who discovered and characterized the signaling molecule nitric oxide received the Nobel prize for Physiology or Medicine. The $975 000 prize was divided equally among pharmacologists Robert Furchgott of the State University of New York in New York City, Louis Ignarro of the University of California, Los Angeles and Ferid Murad at the University of Texas Medical School in Houston. The discovery that a simple gas could act as a signaling molecule between and within cells startled scientists working in vascular biology, and precipitated a flurry of important observations that will have a lasting influence on the practice of medicine. It all began with the publication of Furchgott's work in 1980 describing his discovery of a potent endothelium-derived relaxing factor. 1 This serendipitous work was a result of Furchgott's observation that under certain conditions isolated vessels would relax in response to the purported vasoconstrictor acetylcholine. He found that the seemingly whimsical response of blood vessels depended on whether or not care had been taken during isolation of the vessel to preserve the delicate lining of its lumen. This lining, called the endothelium, is a diaphanous film only one cell layer in thickness, but it exerts significant control over vasomotion, in large part due to its synthesis and release of nitric oxide.
Furchgott's work triggered great interest in the endothelium-derived relaxing factor, but its chemical nature defied characterization because of its short half-life. Then, in 1986, Furchgott, Ignarro and Salvador Moncada independently provided evidence that this endothelium-derived relaxing factor (EDRF) was nitric oxide. [2] [3] [4] Years before, Ferid Murad had worked out the signaling pathway by which nitric oxide-releasing drugs caused vasodilation. 5 Nitric oxide binds to the heme moiety of soluble guanylate cyclase causing the enzyme to generate cyclic guanosine monophosphate (cGMP). The second messenger cGMP subsequently phosphorylates a number of signaling proteins to induce vasodilation. The previous work of Murad was a piece of the puzzle that fell into place with the discovery that EDRF was NO.
NO: a ubiquitous signaling molecule
A measure of the importance of any investigation is the body of work that follows from it. On this count, the discovery of nitric oxide has few equals.
There appears to be no field of medicine or physiology that has not been affected by the discovery of this gaseous signaling molecule. This is in part because most cells are capable of producing nitric oxide, depending upon whether they contain the enzyme nitric oxide synthase. Nitric oxide synthase oxidizes the amino acid l-arginine to citrulline and nitric oxide. 6 There are three isoforms of nitric oxide synthase that are classically recognized as the endothelial, neuronal and macrophage forms. 7 In the endothelial and neuronal cells, NO synthase is a particulate enzyme that is constitutively expressed (although its expression and activity are regulable). By contrast, in the macrophage, NO synthase is a cytosolic enzyme and the expression of which must be induced by cytokines or other factors. As it turns out, the expression of NO synthase can be induced in most cells given the right stimulus. For this reason NO may have diverse actions including vasodilation, neurotransmission, immunomodulation and regulation of cell cycle. NO plays an important role in immune defense, and when generated in large amounts by white blood cells (probably in the form of peroxynitrite anion) it is cytotoxic to pathogens and induces apoptosis in tumor cells. 8, 9 The neuronal form of NO synthase may play an important role in behavior. 10 Although genetically manipulated mice deficient in neuronal NO synthase do not appear to have a learning deficit, they display a disturbing behavioral disorder (they are muricidal). In the vasculature, endothelium-derived nitric oxide is the most potent endogenous vasodilator known, and as discussed below, also plays a critical role in regulating the structure of the blood vessel and its interactions with circulating blood elements.
Role in vascular physiology
Endothelium-derived nitric oxide is the most potent endogenous vasodilator known, and plays a critical role in regulating vasomotion and blood flow. The endothelium releases NO in response to a wide variety of hormonal, neural and physical stimuli. A number of agents that directly cause the vascular smooth muscle to contract also cause the endothelium to release nitric oxide. In a healthy vessel the action of norepinephrine, thrombin, serotonin or other vasoconstrictors is blunted or even reversed to a vasodilation. 7 By contrast, when the endothelium is damaged (as with trauma) or dysfunctional (as with hypercholesterolemia), these agents will cause excessive vasoconstriction. The most common physiological stimulus for vascular NO release is blood flow. Physiologists have recognized for a century the phenomenon of flow-mediated vasodilation. As the flow of blood increases through a conduit vessel, the vessel dilates. This flow-mediated vasodilation requires the integrity of the endothelium, and in most vessels is due largely to the release of NO, although prostacyclin or endothelium-derived hyperpolarizing factor may play greater roles in some circulations. 7, 11 Antagonism of NO synthesis causes a significant rise in systemic and pulmonary resistance, as testimony to its critical role in regulating vascular tone. 12 In addition to its primacy as a vasodilator, NO is also a key regulator of vascular growth. Proliferation of vascular smooth muscle cells in vitro is suppressed by NO-releasing drugs, or by cGMP analogues. 13 The abnormal proliferation of vascular smooth muscle cells that results in restenosis after balloon angioplasty is blocked by NO. [14] [15] [16] Enhancement of vascular NO activity by gene therapy using a plasmid construct encoding NO synthase, or by local administration of the NO precursor l-arginine, increases vascular generation of NO and reduces experimentally induced restenosis. 14, 15 In humans, systemic administration of NOreleasing drugs prior to and during coronary angioplasty has a modest beneficial impact upon lumen diameter which is sustained for 6 months. 16 More recently, NO has been found to be a survival factor for endothelial cells, which enhances their growth. Because angiogenesis requires endothelial cell proliferation, it has been hypothesized that NO may be a critical regulator of angiogenesis. Indeed, the activity of NO synthase appears to be required for the efficacy of many agents of angiogenesis. 17, 18 Finally, NO plays an important role in regulating the interaction of circulating blood elements with the vessel wall. NO inhibits the adherence of white blood cells to the endothelium, in part by interfering with adhesion signaling, and in part by down-regulating the expression of endothelial adhesion molecules and chemokines. [19] [20] [21] Furthermore, NO inhibits platelet adherence and aggregation. 22
Vascular disease: a deficiency of NO
Because NO is such an important regulator of vessel tone, structure and blood fluidity, one might imagine that in states of NO deficiency there would be a tendency for excessive vasoconstriction, thickening of the vessel wall, thrombosis and inflammation. Indeed, this seems to be the case in the most common of vascular diseases, atherosclerosis. In fact, a deficiency of vascular NO may contribute to the development of atherosclerosis. We and others have shown that the usual risk factors for atherosclerosis (hypercholesterolemia, hypertension, tobacco use, diabetes mellitus) are very early in their course associated with the reduced activity of vascular nitric oxide. [23] [24] [25] Moreover, blockade of NO production using pharmacological antagonists of NO synthase accelerates atherosclerosis in animal models. 26 Intriguingly, an endogenous antagonist of NO synthesis has been discovered. 27 Asymmetric dimethylarginine (ADMA) is a competitive inhibitor of NO synthase, and plasma levels of this inhibitor are elevated in atherosclerosis or conditions associated with atherosclerosis. [28] [29] [30] [31] The elevation of plasma ADMA is of sufficient magnitude to reduce vascular NO synthesis. 32 Finally, the plasma level of ADMA correlates better with endothelial vasodilator dysfunction than does LDL cholesterol. 30 ADMA may be a novel risk factor for endothelial dysfunction, and for atherosclerosis. 30, 31 In 121 Japanese with a variety of risk factors for atherosclerosis, age and plasma ADMA levels were better predictors for carotid artery thickness (as meas-Vascular Medicine 1999; 4: 57-60 ured by B-mode ultrasound) than the lipid profile, blood sugar, arterial pressure or tobacco exposure.
Because ADMA is a competitive inhibitor of NO synthase, its effect can be overcome by supplemental l-arginine. Indeed, oral administration of l-arginine to hypercholesterolemic rabbits or mice enhances vascular NO synthesis, and markedly inhibits progression (and even induces regression) of atheroma. [33] [34] [35] Of note, the effect of l-arginine to inhibit atherogenesis in animal models exceeds the effect of lovastatin. 36 These observations suggested a new therapeutic strategy for vascular disease.
A new strategy for vascular disease
In patients with atherosclerosis, there is excessive or inappropriate vasoconstriction, often occurring in segments with obstructive lesions, which has the effect of further limiting flow. The endothelium in these diseased vessels is injured or dysfunctional, and is more adhesive for monocytes, T lymphocytes and platelets. The growth-inhibitory properties of the endothelium are lost. The endothelial derangement has the effect of exacerbating symptoms of atherosclerosis, and of propagating the growth of plaque. However, to the extent that the endothelial dysfunction is reversible, the symptoms may be improved, and the growth of plaque reversed. Accordingly, a new strategy for the treatment of vascular disease is to augment endothelial function. Because NO is a potent vasodilator, and because it inhibits key processes in atherogenesis, it may be thought of as our endogenous self-defense mechanism against atherosclerosis. This paradigm is gaining adherents as evidence accumulates that enhancement of the NO synthase pathway has beneficial clinical effects. One approach to augmenting this endogenous vasoprotective pathway is to administer supplemental amounts of the NO precursor larginine. As previously mentioned, this has the effect of reversing the influence of unhealthy levels of ADMA, the NOS inhibitor. In asymptomatic hypercholesterolemic patients, or in those with coronary artery disease, supplemental l-arginine improves endothelium-dependent vasodilation. [37] [38] [39] The improvement in endothelial vasodilator function has immediate clinical benefits, typically within 1-2 weeks, because of the normalization of vasomotion. In a Mayo Clinic study, oral l-arginine (9 g/day) reduced anginal symptoms by approximately 70% within 1 week. The improvement in symptoms was sustained for the duration of the 6-month study and associated with a 150% absolute increase in coronary blood flow response to acetylcholine. 39 Improvements in treadmill exercise have been reported in patients with coronary or peripheral arterial disease. 40, 41 Endothelial vasodilator function may also be enhanced by the administration of antioxidants, 42 which protect NO from degradation by oxygen-derived free radicals; by enhancing the activity or expression of NO synthase; 43, 44 or by reducing risk factors associated with endothelial dysfunction. 45 Albeit unintended, at least some of the therapeutic efficacy of converting enzyme inhibitors, statins and calcium channel blockers is due to their enhancement of endothelial function. Now that the relevance to cardiovascular therapy is clear, there will be intense efforts to develop endothelialtargeted therapy intentionally. In less than two decades, the serendipitous observation of Furchgott has resulted in an entirely new field of endothelial biology, and a new and promising therapeutic approach to vascular disease. 
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